Press Release |
Research and Markets: PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to 2022
* Reuters is not responsible for the content in this press release.
http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130306:nBw065704a DUBLIN--(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/9llnsp/pharmapoint) has announced the addition of GlobalData's new report "PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to 2022" to their offering. GlobalData has released its new Country report, PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to 2022. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action. The main drivers for growth in this market are the launch of new AEDs, the continued uptake of recent AEDs, and the lower-than-average rate of generic substitution in Spain compared with other countries, although this may change during the forecast period due to government cost-cutting strategies. Scope - Overview of Epilepsy including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in Spain from 2012-2022. - Analysis of the impact of key events as well the drivers and restraints affecting Spain Epilesy market. For more information visit http://www.researchandmarkets.com/research/9llnsp/pharmapoint Source: GlobalData Research and Markets Laura Wood, Senior Manager. firstname.lastname@example.org U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Pharmaceuticals Copyright Business Wire 2013